The following slide deck was published by Molecular Partners AG in conjunction with their 2022 Q2 earnings call.
For further details see:
Molecular Partners AG 2022 Q2 - Results - Earnings Call Presentationhome / stock / mllcf / mllcf news
The following slide deck was published by Molecular Partners AG in conjunction with their 2022 Q2 earnings call.
For further details see:
Molecular Partners AG 2022 Q2 - Results - Earnings Call PresentationMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Proof-of-concept of Switch-DARPin platform established in vivo , enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with ...
MP0712, a 212 Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano Med Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profile First-in-human study in planning...
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favorable and manageable safety profile observed at all tested dose levels Weekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmac...